drugset / Trial / NCT02507011
Beta-blockers in Pulmonary Arterial Hypertension
RandomizedCrossoverDouble-blindTreatment
Summary
The investigators will conduct a, randomized, phase 2, placebo-controlled, double-blinded, crossover trial of carvedilol in 26 PAH patients with World Health Organization functional class II or III symptoms and RV ejection fraction (EF) \< 45% for 6 months.
Timeline
- Start
- 2016-01-31
- Primary completion
- 2019-07-01
- Completion
- 2019-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carvedilol | Other / unclassified | 9.375 mg | — |